Literature DB >> 32531469

Efficacy and safety of rituximab in treating patients with multiple sclerosis (MS): A systematic review and meta-analysis.

Mahsa Ghajarzadeh1, Amirreza Azimi2, Zahra Valizadeh3, Mohammad Ali Sahraian2, Mehdi Mohammadifar4.   

Abstract

Entities:  

Keywords:  Efficacy; Multiple sclerosis; Rituximab

Mesh：

Substances：

Year:  2020        PMID： 32531469     DOI： 10.1016/j.autrev.2020.102585

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN： 1568-9972            Impact factor:   9.754


× No keyword cloud information.
  4 in total

Review 1.  Rituximab for people with multiple sclerosis.

Authors:  Graziella Filippini; Jera Kruja; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2021-11-08

2.  Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.

Authors:  Daniel S Reich; Douglas L Arnold; Patrick Vermersch; Amit Bar-Or; Robert J Fox; Andre Matta; Timothy Turner; Erik Wallström; Xinyan Zhang; Miroslav Mareš; Farit A Khabirov; Anthony Traboulsee
Journal:  Lancet Neurol       Date:  2021-09       Impact factor: 59.935

Review 3.  Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

Authors:  Serena Brancati; Lucia Gozzo; Laura Longo; Daniela Cristina Vitale; Filippo Drago
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

4.  Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.

Authors:  Hao Wang; Juanping Zhou; Yi Li; Lili Wei; Xintong Xu; Jianping Zhang; Kehu Yang; Shihui Wei; Wenfang Zhang
Journal:  Ther Adv Neurol Disord       Date:  2021-12-17       Impact factor: 6.570
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.